Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Blood pressure measurement, Dermatologic examination, Exposure during pregnancy, Gynaecological examination, Physical examination
Clinical narrative: Pregnant; This spontaneous prospective pregnancy case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of EXPOSURE DURING PREGNANCY (Pregnant) in a 30-year-old female patient (gravida 7, para 5) who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Vaginal delivery (Full term Birth. Fetus 1 . Male child) on 04-Oct-2010, Vaginal delivery (Full term Birth. Fetus 1 . Male child) on 08-May-2012, Vaginal delivery (Full term Birth. Fetus 1 . Male child) on 08-Sep-2014, Vaginal delivery (Full term Birth. Fetus 1 . Female child) on 21-Nov-2016, Abortion spontaneous on 30-Dec-2017, Vaginal delivery (Provided regional epidural anesthesia.Full term Birth. Fetus 1 . Female child) on 28-Dec-2018 and PAP smear on 12-Jun-2018. Concurrent medical conditions included Mood change, Nausea and Obesity. Concomitant products included ESCITALOPRAM from 22-Mar-2021 to an unknown date and ESCITALOPRAM OXALATE (LEXAPRO) for Mood change, DOXYLAMINE SUCCINATE (UNISOM [DOXYLAMINE SUCCINATE]) from 17-May-2021 to an unknown date, ONDANSETRON (ZOFRAN [ONDANSETRON]) from 17-May-2021 to an unknown date and VITAMIN B6 for Nausea, PRENATAL [ASCORBIC ACID;BETACAROTENE;BIOTIN;CALCIUM CARBONATE;CALCIUM PANTOTHENATE;CHROMIUM;COLECALCIFEROL;COPPER;CYANOCOBALAMIN;FERROUS FUMARATE;FOLIC ACID;MAGNESIUM OXIDE;MANGANESE;NICOTINAMIDE;POTASSIUM IODIDE;PYRIDOXINE HYDROCHLORIDE;RIBOFLAVIN;S from 12-Apr-2021 to an unknown date for Prenatal care, ACETYLSALICYLIC ACID (ASPIRIN 81) from 17-May-2021 to an unknown date, DOXYLAMINE;PYRIDOXINE from 17-May-2021 to an unknown date, FEXOFENADINE from 14-Apr-2021 to an unknown date, OMEPRAZOLE from 17-May-2021 to an unknown date and ACETYLSALICYLIC ACID (BABY ASPIRIN) for an unknown indication.    In March 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. The patient's last menstrual period was on 14-Mar-2021 and the estimated date of delivery was 19-Dec-2021. On an unknown date, the patient experienced EXPOSURE DURING PREGNANCY (Pregnant) (seriousness criterion hospitalization). The patient was hospitalized from sometime in 2021 to 20-May-2021 due to EXPOSURE DURING PREGNANCY. The patient received mRNA-1273 (Moderna COVID-19 Vaccine) during pregnancy.  At the time of the report, EXPOSURE DURING PREGNANCY (Pregnant) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 17-May-2021, Blood pressure measurement: 116/72 (Inconclusive) Unknown. On 17-May-2021, Dermatologic examination: unknown (normal) No rashes or lesions. On 17-May-2021, Gynaecological examination: unknown (Inconclusive) ABDOMINAL EXAMINATION: Auscultation/inspection/palpitation : no tenderness/guarding/rebound, hepatomegaly, splenomegaly, masses or CVA tenderness and soft and non-distended. Hernia : none palpated.. On 17-May-2021, Physical examination: unknown (normal) General appearance:  Well-nourished, healthy appearing gravida and no acute distress.. On 17-May-2021, Ultrasound foetal: twin.di-di (Inconclusive) 9 week 1 day. On 18-May-2021, Ultrasound foetal: twin.di-di (Inconclusive) 9 week 1 day.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Products known to have been used by the patient, within two weeks prior to the event , included medications ( including supplements, vitamins, herbs , OTC drugs ), illicit/recreational drugs, alcohol. Treatment information was not provided. The patient stated that her appointment for second shot was scheduled on 15 Apr 2021. It was reported that growth sonos planned in third trimester.   Most recent FOLLOW-UP information incorporated above includes: On 20-May-2021: Follow up received on 21 May 2021 included reporter information, medical history added, concomitant products added and details of hospitalization.